WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018026533) MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/026533 International Application No.: PCT/US2017/043112
Publication Date: 08.02.2018 International Filing Date: 20.07.2017
IPC:
C07K 16/18 (2006.01) ,C07K 16/30 (2006.01) ,C12N 15/113 (2010.01) ,A61K 47/68 (2017.01) ,A61P 35/00 (2006.01) ,A61K 39/00 (2006.01)
Applicants: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES[US/US]; National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard, Suite 325, MSC 7660 Bethesda, MD 20852-7660, US
Inventors: HO, Mitchell; US
LI, Nan; US
DIMITROV, Dimiter, S.; US
Agent: CONNOLLY, Jodi, L.; US
Priority Data:
62/369,86102.08.2016US
Title (EN) MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 (GPC2) AND USE THEREOF
(FR) ANTICORPS MONOCLONAUX CIBLANT LE GLYPICAN-2 (GPC2) ET LEUR UTILISATION
Abstract: front page image
(EN) A panel of human variable heavy (VH) single domain monoclonal antibodies specific for cell-surface glypican-2 (GPC2) are described. Methods for the diagnosis and treatment and GPC2- positive cancer are also described. Recombinant immunotoxins comprised of a GPC2-specific VH domain antibody and a clinically used form of Pseudomonas exotoxin A (PE38) were generated and shown to inhibit GPC2-positive neuroblastoma tumor cell growth and inhibit neuroblastoma xenograft growth in nude mice, without significant toxicity. Chimeric antigen receptors comprising a GPC2-specific VH single domain antibody are also described. T cells expressing the GPC2- specific CARs potently killed GPC2 -positive neuroblastoma cells in a dose-dependent manner.
(FR) L'invention concerne un panel d'anticorps monoclonaux à domaine unique (VH) de variable humaine spécifiques du glypican-2 (GPC2) pour des surfaces cellulaires. L'invention concerne également des méthodes de diagnostic et de traitement du cancer à GPC2-positif. Immunotoxines recombinantes constituées d'un anticorps du domaine VH spécifique au GPC2 et d'une forme cliniquement utilisée d'exotoxine A (PE38) de Pseudomonas ont été générées et ont montré qu'elles inhibent la croissance des cellules tumorales de neuroblastomes à GPC2-positif et inhibent la croissance de la xénogreffe de neuroblastome chez les souris nude, sans toxicité significative. L'invention concerne également des récepteurs d'antigène chimériques comprenant un anticorps à domaine unique VH spécifique de GPC2. Les lymphocytes T exprimant les GPC2 spécifiques des CARs sont potentiellement tueuses des cellules de neuroblastome à GPC2-positif d'une manière dépendante de la dose.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)